Almost every family touched by hemangiosarcoma arrives, sooner or later, at the same quiet and aching question. How long? It is one of the hardest questions to ask, and one of the hardest to answer, and we want to meet it here with honesty and with gentleness in equal measure.
This article explains what veterinarians mean when they talk about prognosis, what the numbers genuinely say, and, just as importantly, what those numbers cannot say. We will not soften the truth, because false hope helps no one make loving decisions. But we will also be careful to place the truth in its proper frame, because a statistic, read without context, can take more from a family than it needs to.
What Prognosis Means, and What a Median Is
Prognosis is simply the likely course of a disease, the outlook. Veterinarians most often describe it using a figure called the median survival time, and it is worth understanding exactly what that figure is, because it is so easily misread.
As one veterinary oncology practice explains it clearly, a median is the middle value of a set of outcomes. If the median survival time is six months, that means half of the dogs in that group lived longer than six months and half lived a shorter time. A median is not a prediction, and it is not a deadline. It is a single point in the middle of a wide range of real outcomes, and dogs fall on both sides of it.
The Honest Numbers for Internal Hemangiosarcoma
For the internal, or visceral, forms of hemangiosarcoma, the ones affecting the spleen, heart, and liver, the prognosis is genuinely guarded, and it is kinder to say so plainly.
Drawing on veterinary sources, the general picture is as follows. Without surgery, most dogs with splenic hemangiosarcoma live only a short time, often around a month. With surgery alone, typically removal of the spleen, median survival times most often fall in the range of one to three months. With surgery followed by doxorubicin-based chemotherapy, median survival times reported in the veterinary literature most often range from about four to six or seven months, and even with this combined treatment, the proportion of dogs alive one year after diagnosis remains low, generally below ten to fifteen percent. Hemangiosarcoma affecting the heart tends to carry a survival measured in a similar range of months, made harder by the tumor's location.
These numbers are sobering, and we will not pretend otherwise. Long-term survival with internal hemangiosarcoma is uncommon. And yet, in the same honest breath, it is also true that some dogs live considerably longer than the median suggests. The median is a midpoint, not a limit, and no statistic has ever met your particular dog.
The Skin Form Is a Different Story
There is one genuinely hopeful exception worth knowing. The dermal, or skin, form of hemangiosarcoma behaves very differently from the internal forms. When a skin tumor is truly superficial and is found early and removed completely, the outlook can be far better, and in many cases the surgery is effectively curative. Tumors that sit deeper, in the tissue beneath the skin or within muscle, are more variable, but even there, reported survival times can extend well beyond those seen with the visceral disease. This is one more reason that checking your dog's skin for new lumps is a small habit worth keeping.
What Influences a Dog's Outlook
Prognosis is not a single fixed number. Several things shape it.
The most powerful factor is the stage of the disease, which is how far the cancer has progressed. Veterinary studies consistently find that clinical stage is strongly associated with survival. A dog whose disease is found while it is still confined tends to face a meaningfully different outlook than a dog whose cancer has already spread widely by the time of diagnosis. Whether the tumor has ruptured, whether the liver is involved, and the treatment a family chooses all influence the picture as well. And underlying all of it is the individual dog, because biology varies, and dogs do sometimes surprise everyone who cares for them.
What Chemotherapy Can and Cannot Do
Because chemotherapy is so often part of the prognosis conversation, it helps to understand its role honestly. Surgery removes the visible tumor. Chemotherapy, usually doxorubicin given in a series of treatments, is aimed at the microscopic spread that surgery cannot reach. The evidence shows that adding chemotherapy after surgery does extend median survival compared with surgery alone. It is a real benefit, and at the same time an honest one to describe as modest. Chemotherapy is not a cure for internal hemangiosarcoma.
What can be said with reassurance is that veterinary chemotherapy is generally aimed at preserving quality of life, and most dogs tolerate it well, without the severe effects often associated with chemotherapy in human medicine. Researchers continue to study newer and additional approaches, including gentler ongoing chemotherapy schedules, targeted drugs, and immune-based therapies, in the hope of improving on these numbers. Our article on the history of this disease describes that growing body of research, and the genuine hope within it.
Holding the Numbers Gently
This is the part we most want you to carry away.
A prognosis is information. It is not destiny, and it is not a verdict on your dog. The statistics in this article describe large groups of dogs studied over many years. They cannot describe the specific dog asleep beside you, with their own biology, their own resilience, and their own story still being written. Some dogs outlive every expectation. The median is a midpoint, never a countdown.
It is also worth saying that a number can only measure the length of time. It cannot measure what that time holds. It cannot weigh a slow morning in a patch of sun, a gentle walk, a head resting on a knee. Your dog has no concept of a survival statistic. They know only whether they feel comfortable, whether they are loved, and whether today is a good day. When the focus shifts, as it often gently should, from how long to how well, the goal becomes clear and reachable: as many good, comfortable, loved days as possible, however many there are.
This is also why comfort-focused and palliative care is never a lesser choice. For many families, choosing to protect a dog's peace, rather than to pursue every possible treatment, is the most loving decision available, and it is a valid and tender one. There is no single correct path here. Prognosis exists to help you choose the path that is right for your own dog, with clear eyes and an open heart. Whatever you decide, if it is decided with your dog's comfort held close, it is enough.
A Closing Word
If you are reading this with a recently diagnosed dog, we are so sorry, and we want you to know that you are not walking this road alone. The numbers on this page are hard, and we will not dress them up. But please do not let them crowd out the time you still have. Your dog is not a statistic. They are your companion, and the days ahead, however many, are still yours to fill with gentleness and love. That, in the end, is the part of the prognosis that belongs entirely to you.
Sources and Further Reading
- Cornell University, Riney Canine Health Center: Hemangiosarcoma in Dogs
- Iowa State University, Lloyd Veterinary Medical Center: Canine Splenic Hemangiosarcoma
- Metropolitan Veterinary Associates: Canine Splenic Hemangiosarcoma
- Canine Splenic Hemangiosarcoma: Biological Behavior, Clinical Challenges and Therapeutic Limitations, Animals, 2026
- Survival Time of Dogs with Splenic Hemangiosarcoma Treated by Splenectomy with or without Adjuvant Chemotherapy, 208 cases
- Canine Visceral Hemangiosarcoma Treated with Surgery Alone or Surgery and Doxorubicin
- Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Veterinary Consensus Review
- Your own veterinarian or a board-certified veterinary oncologist, who can speak to your individual dog's outlook